Drug Profile
AJM 347
Alternative Names: AJM-347Latest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator EA Pharma
- Developer EA Pharma; Eisai Inc
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Alpha4beta7 integrin antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Inflammatory bowel diseases
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for phase-I development in Inflammatory-bowel-diseases(In volunteers, In adults) in United Kingdom (PO)
- 25 Apr 2022 Phase-I clinical trials in Inflammatory bowel diseases in European Union (PO) (Eisai Pharma pipeline, April 2022)
- 21 May 2021 Pharmacodynamics data from a preclinical studies in Inflammatory bowel disease presented at the Digestive Disease Week 2021 (DDW-2021)